by GOAI

由GOAI生成

Share To

分享到

Novartis has announced plans to acquire Excellergy, a start-up specializing in allergy treatments, as part of its latest strategic move in the biopharmaceutical sector. In a separate transaction, Otsuka Holdings has finalized the acquisition of Transcend Therapeutics, further expanding its portfolio in mental health therapies.

诺华宣布计划收购专注于过敏治疗的初创公司Excellergy，这是其在生物制药领域的最新战略举措。在另一项交易中，大冢控股已完成对Transcend Therapeutics的收购，进一步扩展其在心理健康治疗领域的业务组合。

These developments highlight ongoing consolidation trends within the pharmaceutical industry..

这些发展突显了制药行业内的持续整合趋势。

The Novartis-Excellergy deal underscores Novartis’ focus on advancing treatments for allergic conditions. Details regarding the financial terms of this acquisition have not been disclosed. Meanwhile, Otsuka’s purchase of Transcend Therapeutics signals its commitment to addressing unmet needs in mental health care.

诺华与Excellergy的交易凸显了诺华对推进过敏性疾病治疗的关注。此项收购的财务条款细节尚未披露。同时，大冢制药对Transcend Therapeutics的收购表明了其致力于满足心理健康护理中未被满足的需求。

The transactions are part of a broader wave of partnerships and acquisitions across the sector, including recent collaborations such as Merck’s agreement with Terns Pharmaceuticals, Gilead Sciences’ partnership with Ouro Biosciences, and Aurinia Pharmaceuticals’ collaboration with Kezar Life Sciences.

这些交易是该行业更广泛的合作与收购浪潮的一部分，近期的合作包括默克与Terns Pharmaceuticals的协议、吉利德科学与Ouro Biosciences的合作，以及Aurinia Pharmaceuticals与Kezar Life Sciences的合作。

These deals reflect an industry-wide effort to bolster pipelines and expand therapeutic offerings through targeted acquisitions and alliances..

这些交易反映了整个行业通过有针对性的收购和联盟来加强产品线和扩大治疗产品供应的努力。

Newsflash | Powered by GeneOnline AI

快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: March 30, 2026

日期：2026年3月30日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章